Lv71
3470 积分 2022-04-01 加入
BCL ‐2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma
1小时前
待确认
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma
1个月前
已完结
Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma
1个月前
已完结
Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review
1个月前
已完结
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy
1个月前
已完结
Prognostic Role of Circular RNAs in Mantle Cell Lymphoma: A Competing Endogenous RNA Network Analysis
1个月前
已关闭
Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study
1个月前
已完结
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
1个月前
已完结
Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients?
2个月前
已完结
皖公网安备34019202002308
